13,120 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Purchased by Semanteon Capital Management LP

Semanteon Capital Management LP purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the fourth quarter, Holdings Channel.com reports. The firm purchased 13,120 shares of the biotechnology company’s stock, valued at approximately $1,265,000. Sarepta Therapeutics accounts for approximately 0.9% of Semanteon Capital Management LP’s portfolio, making the stock its 10th largest position.

A number of other institutional investors have also recently bought and sold shares of SRPT. Montag A & Associates Inc. purchased a new position in Sarepta Therapeutics in the 3rd quarter worth about $30,000. Cary Street Partners Investment Advisory LLC grew its stake in Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 154 shares in the last quarter. CWM LLC grew its stake in Sarepta Therapeutics by 178.7% during the 4th quarter. CWM LLC now owns 577 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 370 shares in the last quarter. Fifth Third Bancorp grew its stake in Sarepta Therapeutics by 1,215.8% during the 4th quarter. Fifth Third Bancorp now owns 1,000 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 924 shares in the last quarter. Finally, Hudson Capital Management LLC purchased a new position in Sarepta Therapeutics during the 3rd quarter valued at about $206,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Buying and Selling

In related news, Director Kathryn Jean Boor sold 761 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the sale, the director now directly owns 7,516 shares in the company, valued at approximately $923,941.88. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CFO Ian Michael Estepan sold 1,200 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.30, for a total transaction of $153,960.00. Following the completion of the transaction, the chief financial officer now directly owns 39,114 shares in the company, valued at $5,018,326.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the transaction, the director now owns 7,516 shares of the company’s stock, valued at $923,941.88. The disclosure for this sale can be found here. In the last ninety days, insiders sold 22,096 shares of company stock worth $2,739,419. 7.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

SRPT has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $128.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. Needham & Company LLC lowered their target price on Sarepta Therapeutics from $169.00 to $166.00 and set a “buy” rating on the stock in a research note on Thursday, February 29th. Barclays lifted their target price on Sarepta Therapeutics from $141.00 to $185.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th. TheStreet raised Sarepta Therapeutics from a “d” rating to a “c-” rating in a research note on Monday, March 4th. Finally, Mizuho lifted their target price on Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Wednesday, February 14th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $158.38.

Sarepta Therapeutics Stock Performance

SRPT traded up $3.14 on Thursday, hitting $127.39. The company had a trading volume of 1,694,283 shares, compared to its average volume of 994,316. The company’s fifty day moving average price is $126.22 and its 200 day moving average price is $110.43. Sarepta Therapeutics, Inc. has a 1-year low of $55.25 and a 1-year high of $159.89. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.95 and a quick ratio of 3.45. The stock has a market cap of $11.96 billion, a price-to-earnings ratio of -20.82 and a beta of 0.94.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.50. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The firm had revenue of $396.80 million during the quarter, compared to analyst estimates of $387.18 million. During the same period in the previous year, the company earned ($1.24) EPS. The company’s revenue for the quarter was up 53.6% on a year-over-year basis. Equities analysts predict that Sarepta Therapeutics, Inc. will post 2.13 earnings per share for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.